Cargando…

Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial

BACKGROUND: Osteoarthritis (OA) is the most frequent cause of disability in elderly people. In daily practice, the main objective of the physician is to reduce patient symptoms using treatments without adverse effects. However, the most prescribed treatment to manage OA symptoms remains nonsteroidal...

Descripción completa

Detalles Bibliográficos
Autores principales: Henrotin, Yves, Cozannet, Romain Le, Fança-Berthon, Pascale, Truillet, Romain, Cohen-Solhal, Martine, DunnGalvin, Gillian, Grouin, Jean-Marie, Doolan, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261022/
https://www.ncbi.nlm.nih.gov/pubmed/35799169
http://dx.doi.org/10.1186/s12891-022-05612-2
_version_ 1784742175667388416
author Henrotin, Yves
Cozannet, Romain Le
Fança-Berthon, Pascale
Truillet, Romain
Cohen-Solhal, Martine
DunnGalvin, Gillian
Grouin, Jean-Marie
Doolan, Andrea
author_facet Henrotin, Yves
Cozannet, Romain Le
Fança-Berthon, Pascale
Truillet, Romain
Cohen-Solhal, Martine
DunnGalvin, Gillian
Grouin, Jean-Marie
Doolan, Andrea
author_sort Henrotin, Yves
collection PubMed
description BACKGROUND: Osteoarthritis (OA) is the most frequent cause of disability in elderly people. In daily practice, the main objective of the physician is to reduce patient symptoms using treatments without adverse effects. However, the most prescribed treatment to manage OA symptoms remains nonsteroidal anti-inflammatory drugs which are associated with severe adverse effects. Therefore, we need a safe alternative to managing OA. One candidate is Rubus idaeus leaf extracts known to inhibit inflammatory responses. OBJECTIVE: This study aimed to evaluate the effects of a 12-weeks intervention with an ethanolic extract from Rubus idaeus leaf on symptoms of knee osteoarthritis. METHOD: The study was a randomized, double-blind, placebo-controlled, monocentric trial of 198 participants with femorotibial osteoarthritis. Participants were randomized equally to receive one daily during 3 months either 1 capsule of Rubus idaeus leaf extract 400 mg, 1 capsule of Rubus idaeus leaf extract 200 mg, or 1 capsule of placebo. The participants were assessed at baseline and after one and three months of treatment. The primary endpoint was an absolute change of the Western Ontario McMaster osteoarthritis index (WOMAC) pain subscale. The secondary endpoints were WOMAC global score, stiffness and function sub-scales, knee pain VAS score at walking, the Short Form (SF)-36, the Short Physical Performance Battery (SPPB), the 20-m walk test, and the International Physical Activity Questionnaire (IPAQ) and Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) responders rate. Statistical analyses were conducted on the intent-to-treat (ITT) population. RESULTS: In the Intention-to-treat population, WOMAC pain was not significantly modified by Rubus idaeus leaf extract compared to placebo. In contrast, Rubus idaeus leaf extract 400 mg after 12 weeks of treatment significantly reduced pain measured by the VAS. The mean pain decrease induced by Rubus ideaus leaf extract was over -7 mm which is clinically relevant and reached a clinically statistical difference compared to placebo with the highest dose. Rubus Ideaus was not significantly more efficient than the placebo on WOMAC global score, stiffness, and physical function subscores, IPAQ, SF-36, walking distance in treadmill test, SPPB, and evaluation of associated treatments needed to manage OA. CONCLUSION: Rubus idaeus leaf extract was well tolerated and effective to relieve pain in a patient with knee osteoarthritis. TRIAL REGISTRATION: NCT03703024 (11/10/2018). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-022-05612-2.
format Online
Article
Text
id pubmed-9261022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92610222022-07-08 Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial Henrotin, Yves Cozannet, Romain Le Fança-Berthon, Pascale Truillet, Romain Cohen-Solhal, Martine DunnGalvin, Gillian Grouin, Jean-Marie Doolan, Andrea BMC Musculoskelet Disord Research BACKGROUND: Osteoarthritis (OA) is the most frequent cause of disability in elderly people. In daily practice, the main objective of the physician is to reduce patient symptoms using treatments without adverse effects. However, the most prescribed treatment to manage OA symptoms remains nonsteroidal anti-inflammatory drugs which are associated with severe adverse effects. Therefore, we need a safe alternative to managing OA. One candidate is Rubus idaeus leaf extracts known to inhibit inflammatory responses. OBJECTIVE: This study aimed to evaluate the effects of a 12-weeks intervention with an ethanolic extract from Rubus idaeus leaf on symptoms of knee osteoarthritis. METHOD: The study was a randomized, double-blind, placebo-controlled, monocentric trial of 198 participants with femorotibial osteoarthritis. Participants were randomized equally to receive one daily during 3 months either 1 capsule of Rubus idaeus leaf extract 400 mg, 1 capsule of Rubus idaeus leaf extract 200 mg, or 1 capsule of placebo. The participants were assessed at baseline and after one and three months of treatment. The primary endpoint was an absolute change of the Western Ontario McMaster osteoarthritis index (WOMAC) pain subscale. The secondary endpoints were WOMAC global score, stiffness and function sub-scales, knee pain VAS score at walking, the Short Form (SF)-36, the Short Physical Performance Battery (SPPB), the 20-m walk test, and the International Physical Activity Questionnaire (IPAQ) and Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) responders rate. Statistical analyses were conducted on the intent-to-treat (ITT) population. RESULTS: In the Intention-to-treat population, WOMAC pain was not significantly modified by Rubus idaeus leaf extract compared to placebo. In contrast, Rubus idaeus leaf extract 400 mg after 12 weeks of treatment significantly reduced pain measured by the VAS. The mean pain decrease induced by Rubus ideaus leaf extract was over -7 mm which is clinically relevant and reached a clinically statistical difference compared to placebo with the highest dose. Rubus Ideaus was not significantly more efficient than the placebo on WOMAC global score, stiffness, and physical function subscores, IPAQ, SF-36, walking distance in treadmill test, SPPB, and evaluation of associated treatments needed to manage OA. CONCLUSION: Rubus idaeus leaf extract was well tolerated and effective to relieve pain in a patient with knee osteoarthritis. TRIAL REGISTRATION: NCT03703024 (11/10/2018). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-022-05612-2. BioMed Central 2022-07-07 /pmc/articles/PMC9261022/ /pubmed/35799169 http://dx.doi.org/10.1186/s12891-022-05612-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Henrotin, Yves
Cozannet, Romain Le
Fança-Berthon, Pascale
Truillet, Romain
Cohen-Solhal, Martine
DunnGalvin, Gillian
Grouin, Jean-Marie
Doolan, Andrea
Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title_full Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title_fullStr Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title_full_unstemmed Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title_short Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial
title_sort rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase ii double-blind randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261022/
https://www.ncbi.nlm.nih.gov/pubmed/35799169
http://dx.doi.org/10.1186/s12891-022-05612-2
work_keys_str_mv AT henrotinyves rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT cozannetromainle rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT fancaberthonpascale rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT truilletromain rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT cohensolhalmartine rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT dunngalvingillian rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT grouinjeanmarie rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial
AT doolanandrea rubusidaeusextractimprovessymptomsinkneeosteoarthritispatientsresultsfromaphaseiidoubleblindrandomizedcontrolledtrial